)
Shares of Suven Life Sciences are trading higher by 2.7% at Rs 218.50 after their third new chemical entity (NCE) SUVN-D4010 commenced phase-1 clinical trial in US.
SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s disease and other dementias.
The company stated that the third compound from the pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer’s and Schizophrenia, a high unmet medical need which has huge market potential globally, said Venkat Jasti, CEO of Suven to the BSE in a filing.
The stock opened at Rs 215.15 and touched a high of Rs 222 on the BSE. A total of 78,453 shares changed hands on the BSE so far.
